The Food and Drug Administration (FDA) has recommended changes to the prescribing information for a medication used to treat Crohn’s disease due to an increased risk of melanoma. Merck & Co. Inc. was asked to update the label for the drug, known as Corticosteroids, which includes prednisone and budesonide. The FDA’s decision comes after a review of new data that showed an increased risk of melanoma in patients taking the drugs for long periods of time.
